FY2026 EPS Estimate for Kura Oncology Lifted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Analysts at Brookline Capital Management raised their FY2026 earnings estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, November 7th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of $1.26 per share for the year, up from their previous estimate of $1.22. The consensus estimate for Kura Oncology's current full-year earnings is ($2.46) per share.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.04. During the same period last year, the business earned ($0.53) earnings per share. Kura Oncology's revenue for the quarter was up .0% on a year-over-year basis.

Several other analysts have also recently weighed in on the company. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a report on Wednesday, November 6th. HC Wainwright reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday, November 6th. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. Finally, StockNews.com downgraded Kura Oncology from a "hold" rating to a "sell" rating in a research note on Thursday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $28.83.

Kura Oncology Price Performance

Shares of KURA traded down $0.12 during mid-day trading on Monday, hitting $17.56. 484,306 shares of the company traded hands, compared to its average volume of 890,257. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $18.71 and a 200 day moving average of $19.99. Kura Oncology has a one year low of $8.17 and a one year high of $24.17. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.44 and a beta of 0.86.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in Kura Oncology during the third quarter worth about $25,000. SG Americas Securities LLC bought a new stake in shares of Kura Oncology during the 1st quarter worth approximately $110,000. Quarry LP acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at approximately $196,000. Entropy Technologies LP bought a new position in shares of Kura Oncology in the first quarter valued at $218,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company's stock valued at $288,000 after buying an additional 5,788 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.